News

Press Releases

Lance Stewart, Ph.D., M.B.A., Joins the Allen Institute for Brain Science as Senior Director of Alliances

May 29, 2012 | Download PDF

The Allen Institute for Brain Science, a nonprofit medical research organization dedicated to accelerating understanding of the human brain, announced today the appointment of Lance Stewart, Ph.D., M.B.A., as Senior Director of Alliances. In this newly created position, Stewart will seek collaborations with biotechnology and pharmaceutical companies to further broaden the reach of the Allen Institute's efforts and create additional open public data sets for the research community.

"Since inception, a central goal of the Allen Institute has been to maximize the impact we can make on neuroscience," said Allan Jones, the Allen Institute's chief executive officer. "Lance's knowledge of the current R&D landscape and experience leading productive industry partnerships will be a tremendous asset as we seek to expand the applications of our established research platforms to further accelerate progress in brain research."

While the Allen Institute's primary focus will remain on basic science, its unique large-scale data production capabilities, which have generated gold-standard datasets in neuroscience, can be leveraged further for translational applications in collaboration with industry partners.

"With industry pulling back on neuroscience research allocations, the Allen Institute capabilities offer an excellent opportunity to fill a critical gap," said Stewart. "In the field of neuroscience I see a wealth of congruencies. I aim to bring parties together in collaborations that will both help advance the R&D programs of biotechnology and pharmaceutical partners and provide valuable new data to the broader scientific community."

Stewart brings over 15 years of experience in life sciences partnering and entrepreneurial start-up activities. He co-founded the biotechnology company Emerald BioStructures in 1998, leading its growth as a business unit within two publicly traded companies, and becoming CEO in 2009 upon its spin-out. During his tenure at Emerald, Stewart oversaw contract research activities and managed several multi-year collaborations in technology development and structure-based drug design, including the development of drug candidates for improvement of memory and cognition. Stewart earned his Ph.D. in biochemistry and virology from Cornell University, served as a postdoctoral fellow and research assistant professor at the University of Washington, and later earned his Executive M.B.A. at the University of Washington's Foster School of Business.

0